A PHASE 3, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY WITH AN OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ORAL RILZABRUTINIB (PRN1008) IN ADULTS AND ADOLESCENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

Registry ID

PRN1008-018 (EFC17093)

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

PRINCIPIA BIOPHARMA INC

Start date

2023-07-12

Last update

2020-12-01

Conditions

• IMMUNE THROMBOCYTOPENIA (ITP)

Related clinical trials

• AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMOBOCYTOPENIA
• A SINGLE ARM, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY STUDY OF ROMIPLOSTIM IN THROMBOCYTOPENIC PEDIATRIC SUBJECTS WITH IMMUNE THROMBOCYTOPENIA (ITP)
• OPEN LABEL, ADAPTIVE DESIGN, ASCENDING, MULTIPLE-DOSE STUDY TO EVALUATE SAFETY AND EFFICACY OF BMS-986004 (ANTI-CD40L DAB) IN ADULT SUBJECTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)

View on source registry